Prospective real-world evidence study will test whether AI-powered pregnancy monitoring catches danger earlier — and build the clinical and economic case for a pilot-to-payment pathway.
BlueprintNav, an oncology patient navigation technology company, has closed its pre-seed round at $777,500 — exceeding its original $750,000 target — and secured a $50,000 Proof of Commercialization Award from the Iowa Economic Development Authority, bringing total early-stage funding to $827,500.
Project Connect will fast-track U.S. adoption of Medical AI’s deep-learning “digital biomarker” technology — bringing cardiologist-grade risk detection to the nearly half of U.S. counties without a single cardiologist
HITLAB will lead an independent real-world evidence study of MyCareGorithm's visual oncology consultation platform, measuring its impact on patient understanding, shared decision-making, and care team workflow
This report presents HITLAB’s independent evaluation of the VitalFriend platform, an automated remote patient monitoring and care coordination solution designed to support proactive senior care, strengthen health information visibility across assisted living environments, and support timely review of resident health information by caregivers through passive monitoring and connected caregiving infrastructure.
Immunotherapy resistance remains a critical limitation in oncology, particularly in microsatellite stable (MSS) tumors. ENB-003, a first-in-class selective endothelin B receptor (ETBR) inhibitor, targets immune exclusion by restoring T-cell trafficking into tumors.
